TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04991155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
Study: NCT03116607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient education/ recommendations to the health team
Description: The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge that includes an analysis of the therapy indicated by the physician, evaluating the safer alternatives for the type of patient and the special conditions of their pathology, with emphasis on Assessments of effectiveness, safety and tolerability of medication, drug interactions, possible adverse events, dose adjustments as necessary according to patient conditions; Verification that the administration is optimal, including the choice of the best route for this and the time in which the drugs are infused to the patient.
Study: NCT02607891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT02532075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Warm Up
Description: Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
Study: NCT02607891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT00003644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT04970160

Intervention type: PROCEDURE
Intervention: Classic ASARP
Description: Anterior Sagittal anorectoplasty

Intervention type: PROCEDURE
Intervention: Modified ASARP
Description: External anal sphincter preservation
Study: NCT02532075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory Warm Up
Description: Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Warm Up
Description: Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
Study: NCT03624959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin
Study: NCT01855828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
Study: NCT01331629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART-THERAPIE
Description: 8 sessions of art therapy during radiotherapy
Study: NCT04087434

Intervention type: DEVICE
Intervention: Brain Gauge Prospective and Healthy Control
Description: The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.

Intervention type: DEVICE
Intervention: Brain Gauge Prospective and Healthy Control
Description: The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.
Study: NCT02242981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally
Study: NCT01151605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin infusion
Description: insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin infusion
Description: insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl
Study: NCT00003644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02318511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee injection
Description: Injection into knee for the treatment of Osteoarthritis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee injection
Description: Injection into knee for the treatment of Osteoarthritis

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Knee injection
Description: Injection into knee for the treatment of Osteoarthritis
Study: NCT00664599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytotoxic Combination
Description: Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
Study: NCT00799409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/ CONCERTA (methylphenidate HCl)
Description: Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
Study: NCT02532075

Intervention type: OTHER
Group type: OTHER
Intervention: Control Trial
Description: Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
Study: NCT02318511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReNu amniotic allograft

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline
Study: NCT00799409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONCERTA (methylphenidate HCl) / Placebo
Description: Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
Study: NCT02318511

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Study: NCT03683849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: One hour of training, twice a week, for six months.
Study: NCT00487747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 48 weeks
Study: NCT03683849

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: One hour of training, twice a week, for six months.
Study: NCT03543059

Intervention type: DRUG
Intervention: GnRH analogue
Description: gonadotrophin releasing hormone analogue
Study: NCT00825344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg subcutaenous preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given subcutaneously preoperatively
Study: NCT00895596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380
Description: Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380
Description: Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
Study: NCT01235767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
Study: NCT02709889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
Study: NCT03637959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Vibrations with Ultrasound Shear Wave Imaging
Description: Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.
Study: NCT03700931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating recall condition
Description: Recall of eating episodes would increase subsequent intake of fruit or vegetable items

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-eating recall condition
Description: Recall of non-eating episodes would not influence subsequent intake of fruit or vegetable items
Study: NCT03236935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: pan-nitric oxide synthase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor
Study: NCT04184921

Intervention type: DRUG
Intervention: Aspirin 100mg
Description: Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
Study: NCT00807716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking skill group
Description: 12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual physiotherapy care
Description: physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
Study: NCT04613492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI9253
Description: Participants will receive either Single dose MEDI9253 or Multiple Dose MEDI9253; sequentially or concurrent with Durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI9253
Description: Participants will receive either Single dose MEDI9253 or Multiple Dose MEDI9253; sequentially or concurrent with Durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI9253
Description: Participants will receive either Single dose MEDI9253 or Multiple Dose MEDI9253; sequentially or concurrent with Durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab treatment will be started sequentially or concurrently with MEDI9253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab treatment will be started sequentially or concurrently with MEDI9253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab treatment will be started sequentially or concurrently with MEDI9253
Study: NCT02558439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03138590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS
Description: Transcranial Direct Current Stimulation targeting the trigeminal nerve

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS
Description: Transcranial Direct Current Stimulation targeting the trigeminal nerve
Study: NCT01657812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery.
Study: NCT01151605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin infusion
Description: insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose infusion
Description: Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose infusion
Description: Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose infusion
Description: Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Infusion
Description: Saline will be infused at 100ml/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Infusion
Description: Saline will be infused at 100ml/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Infusion
Description: Saline will be infused at 100ml/hr
Study: NCT02226198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: Active drug will be taken taken orally, QD, either in the morning or in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will be taken taken orally, QD, either in the morning or in the evening
Study: NCT04126720

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: topical corticosteroids and vitamin E suplements
Study: NCT03845907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gen 1B
Description: Diagnostic Ultrasound and Optoacoustic Imaging
Study: NCT01657812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery.
Study: NCT04126720

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroid and placebo capsules
Study: NCT03065842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abortion- and contraceptive-use stigma reduction program
Description: An abortion- and contraceptive-use stigma reduction intervention (3-weeks), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.~The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Standards
Description: Usual standards according to the school curriculum in Kenya.
Study: NCT00569309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae
Description: Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory correlative studies
Description: Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
Study: NCT03845907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gen 1
Description: Diagnostic Ultrasound and Optoacoustic Imaging
Study: NCT00569309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
Study: NCT02967692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dabrafenib
Description: Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trametinib
Description: Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
Study: NCT04202146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management + Motivational Interviewing
Description: Seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling on cannabis use and relapse.